| ［1］ Berg K. A new serum type system in man——the Lp system ［J］. Acta Pathol Microbiol Scand, 1963, 59:369382. ［2］ Koschinsky ML. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers［J］. Cardiovasc Hematol Disord Drug Targets, 2006, 6(4):267278. ［3］ Kamstrup PR, TybjaergHansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction ［J］. JAMA, 2009, 301(22):23312339. ［4］ Scriver CR, Beaudet AL, Sly WS, et al. The metabolic and molecular bases of inherited disease ［M］.8th ed. New York: McGrawHill, 2001: 27532787. ［5］ Matthews KA, Sowers MF, Derby CA, et al. Ethnic differences in cardiovascular risk factor burden among middleaged women: study of women′s health across the nation (SWAN)［J］.Am Heart J, 2005,149(6):10661073. ［6］ Tate JR,Rifai N,Berg K, et al. International federation of clinical chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators［J］.Clin Chem,1998,44(8 Pt 1):16291640. ［7］ Tate JR, Berg K, Couderc R, et al. International federation of clinical chemistry and laboratory medicine (IFCC) standardization project for the measurement of lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a) ［J］. Clin Chem Lab Med,1999, 37(10):949958. ［8］ Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions［J］. Clin Chem, 2003, 49(11):17851796. ［9］ National Institutes of Health. National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ) ［S］. 025215, NIH,2002. ［10］ Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality［J］. JAMA, 2009,302(4):412423. ［11］ Kamstrup PR, Benn M, TybjaergHansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study［J］. Circulation, 2008, 117(2):176184. ［12］ Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status［J］. Eur Heart J, 2010, 31(23):28442853. |
